Clinical trials
Recruiting Carcinoma, Transitional Cell trials in Japan
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
12 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2024 | 2 |
| 2025 | 4 |
| 2026 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 12 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Daiichi Sankyo | 2 |
| Astellas Pharma Global Development, Inc. | 1 |
| AstraZeneca | 1 |
| Bristol-Myers Squibb | 1 |
| Eli Lilly and Company | 1 |
| Genmab | 1 |
| Nagoya University | 1 |
| Pfizer | 1 |
| Seagen, a wholly owned subsidiary of Pfizer | 1 |
| Tampere University Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Transitional Cell | 12 |
| Urinary Bladder Neoplasms | 7 |
| Carcinoma, Non-Small-Cell Lung | 3 |
| Ovarian Neoplasms | 3 |
| Squamous Cell Carcinoma of Head and Neck | 3 |
| Uterine Cervical Neoplasms | 3 |
| Biliary Tract Neoplasms | 2 |
| Breast Neoplasms | 2 |
| Carcinoma | 2 |
| Carcinoma, Neuroendocrine | 2 |
Trials
Showing 1 to 12 of 12. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.